NCT02872233 is a NA clinical trial of BAY 987519 in Sunscreen Agents, sponsored by Bayer.

Who is sponsoring NCT02872233?

NCT02872233 is sponsored by Bayer.

What drugs are being tested in NCT02872233?

Interventions in NCT02872233: BAY 987519, SPF 15 Control.

What condition does NCT02872233 study?

NCT02872233 studies Sunscreen Agents.

Is NCT02872233 still recruiting?

NCT02872233 is currently completed. Last updated 12 December 2018.

Last reviewed 2018-12-12 · How we verify

NCT02872233

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay

Completed NA Last updated 12 December 2018

What this trial tests

NA trial testing BAY 987519 in Sunscreen Agents in 6 participants. Completed in 10 June 2015.

Timeline

26 May 2015

Primary endpoint
10 June 2015

10 June 2015

Quick facts

Lead sponsor	Bayer
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	6
Start date	26 May 2015
Primary completion	10 June 2015
Estimated completion	10 June 2015
Sites	1 location across United States

Drugs / interventions tested

BAY 987519 — full drug profile →
SPF 15 Control — full drug profile →

Conditions studied

Sunscreen Agents — all drugs for Sunscreen Agents →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 70, any sex, with Sunscreen Agents. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the effectiveness of a sunscreen product by determining its Sun Protection Factor (SPF) on the skin of human subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of BAY 987519

Trials testing the same drug.

NCT02857738 — Sun Protection Factor (SPF) - Static and Water Resistant Assay · NA · completed

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02872233 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 12 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02872233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing